Home  »  Trending   »  ZIOPHARM Oncology Inc. (ZIOP) upgraded Issued by W...

ZIOPHARM Oncology Inc. (ZIOP) upgraded Issued by Wall Street Gurus

Share on facebook
Share on twitter
Share on linkedin
Share on whatsapp

ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) went down by -5.51% from its latest closing price compared to the recent 1-year high of $5.95. The company’s stock price has collected -6.45% of loss in the last five trading sessions. Press Release reported on 11/09/21 that Ziopharm Oncology Presents Preclinical Data Supporting TCR-T Library Approach at the Society for Immunotherapy of Cancer 2021 Annual Meeting

Is It Worth Investing in ZIOPHARM Oncology Inc. (NASDAQ :ZIOP) Right Now?

Plus, the 36-month beta value for ZIOP is at 1.69.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free


ZIOP currently public float of 194.69M and currently shorts hold a 17.48% ratio of that float. Today, the average trading volume of ZIOP was 2.19M shares.

ZIOP’s Market Performance

ZIOP stocks went down by -6.45% for the week, with a monthly drop of -21.91% and a quarterly performance of -46.01%, while its annual performance rate touched -68.92%. The volatility ratio for the week stands at 7.36% while the volatility levels for the past 30 days are set at 8.55% for ZIOPHARM Oncology Inc.. The simple moving average for the period of the last 20 days is -17.62% for ZIOP stocks with a simple moving average of -56.51% for the last 200 days.

Analysts’ Opinion of ZIOP

Jefferies, on the other hand, stated in their research note that they expect to see ZIOP reach a price target of $5, previously predicting the price at $7. The rating they have provided for ZIOP stocks is “Hold” according to the report published on March 12th, 2021.

ZIOP Trading at -28.04% from the 50-Day Moving Average

After a stumble in the market that brought ZIOP to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -84.12% of loss for the given period.

Volatility was left at 8.55%, however, over the last 30 days, the volatility rate increased by 7.36%, as shares sank -19.92% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -42.03% lower at present.

During the last 5 trading sessions, ZIOP fell by -6.45%, which changed the moving average for the period of 200-days by -71.96% in comparison to the 20-day moving average, which settled at $1.1353. In addition, ZIOPHARM Oncology Inc. saw -13.31% in overturn over a single year, with a tendency to cut further losses.

Insider Trading

Reports are indicating that there were more than several insider trading activities at ZIOP starting from De Groot Eleanor, who sale 20,132 shares at the price of $1.27 back on Dec 22. After this action, De Groot Eleanor now owns 237,106 shares of ZIOPHARM Oncology Inc., valued at $25,568 using the latest closing price.

Boyle Kevin S. Sr., the Chief Executive Officer of ZIOPHARM Oncology Inc., purchase 9,116 shares at $1.40 during a trade that took place back on Nov 17, which means that Boyle Kevin S. Sr. is holding 885,000 shares at $12,762 based on the most recent closing price.

Stock Fundamentals for ZIOP

Equity return is now at value -92.80, with -72.50 for asset returns.

>> 7 Top Picks for the Post-Pandemic Economy <<

Leave a Comment

Your email address will not be published. Required fields are marked *

Is Teradyne Inc. (TER) a Keeper?

Teradyne Inc. (NASDAQ:TER) went up by 3.99% from its latest closing price compared to the recent 1-year high of $168.91. The company’s stock price has




Download Free eBook For


100% free. stop anytime no spam